AI Article Synopsis
Article Abstract
Fanconi anemia (FA) is a rare cancer predisposition disease caused by mutations in at least 12 genes encoding proteins that cooperate to maintain genomic integrity. Variants of FA genes, including FANCG, have been identified in human population screening, but their potential reduction in protein function and role in cancer susceptibility is unclear. To test for possible dysfunction, we constructed plasmids containing four FANCG polymorphisms found in the human population and introduced them in the Fancg-deficient (fancg) KO40 line derived from AA8 hamster CHO cells. Expression of wild-type human FANCG provided fancg cells with complete phenotypic correction as assessed by resistance to the DNA crosslinking agent mitomycin C (MMC), thus providing a sensitive test for detecting the degree of complementation activity for the FANCG variants. We found that all four variants conferred levels of mitomycin C resistance as well as restoration of monoubiquitination of Fancd2, a key indicator of a functional FA protein pathway, similar to those observed in wild-type transfectants. Under the same conditions, the L71P amino acid substitution mutant, identified in an FA patient, gave no complementation. Using this novel system for determining FANCG functionality, we detect no decrement in function of the human FANCG polymorphic variants examined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mrfmmm.2006.07.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chemical Carcinogen (3-Methylcholanthrene)-induced Pleomorphic Rhabdomyosarcomas in Fanconi Anemia Fancd2-/-, Fancg-/- (C57BL/6), Fancd2-/- (129/Sv) Mice.
In Vivo
October 2024
Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, U.S.A.
Article Synopsis
- - Radiation oncologists hesitate to treat cancer in Fanconi Anemia (FA) patients due to their inability to repair DNA strand breaks, leading to concerns about normal tissue damage during therapy.
- - Researchers created transplantable tumors in different strains of FA mice to study the impacts of radiation and chemotherapy on cancer development and progression.
- - The established FA tumor cell lines can serve as crucial models for testing innovative radiation therapy methods and treatment combinations tailored for radiosensitive FA patients.
Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.
Front Med (Lausanne)
October 2024
University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, United States.
Article Synopsis
- Recent research has expanded the concept of "FA signaling" to include over 30 proteins involved in DNA Damage Response (DDR), making it the largest cellular defense network against DNA damage.
- Different human cancers display unique mutational profiles related to DDR/FA signaling, with ATM and BRCA2 being major players across many cancer types, while genes like FANCT predominate in breast and liver cancers.
- Understanding these mutation patterns is crucial, as they greatly influence patient survival and treatment outcomes, potentially guiding more effective therapeutic strategies for various cancers.
Clinicopathological and molecular genetic insights into EBV-positive inflammatory follicular dendritic cell sarcoma.
Hum Pathol
November 2024
Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China. Electronic address:
Article Synopsis
- - This study focused on analyzing 12 cases of Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV + IFDCS) to understand its clinical and pathological features, which are not fully described.
- - Patients ranged in age from 21 to 84 years, with a predominance of females, and all were alive at the last follow-up despite some experiencing recurrence or metastasis; various subtypes were identified within the cases.
- - The study revealed significant differences in marker expressions between EBV + IFDCS and traditional follicular dendritic cell sarcoma (FDCS), along with unique genetic mutations and variations that were observed, contributing to a better understanding of this rare condition
A comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer.
Cancer Med
August 2024
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Article Synopsis
- Monoallelic germline pathogenic variants in certain Fanconi anemia genes are known to increase breast and ovarian cancer risk, but the effects of variants in FANCG/XRCC9 remain unclear.
- Researchers found that the frequency of truncating variants in FANCG did not significantly differ between breast cancer, ovarian cancer patients, and controls.
- The study concludes that heterozygous germline FANCG variants are unlikely to play a role in developing breast or ovarian cancer.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Oncologist
July 2024
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
Background: Uterine leiomyosarcoma (uLMS) represents one of the most common sarcoma histotypes, demonstrating an overall dismal prognosis. Previous studies reported uLMS to carry recurrent somatic BRCA2 homozygous deletions, related to significant clinical benefits from the use of PARP inhibitors.
Methods: To investigate the prevalence in uLMS of genomic alterations (alt) in BRCA2 and other homologous recombination (HR) and DNA damage response (DDR) genes, cBioPortal was accessed and data were retrieved from studies including pan-sarcoma histologies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!